In the realm of dry eye therapeutics, our investigation focuses on the promising checkpoint inhibitor PD-L1, while drawing insights from established treatments like cyclosporine A, a well-known calcineurin inhibitor which modulates the immune response by inhibiting T cell activation and cytokine release. The gene discussed is CD274; the disease is dry eye syndrome.